Gout – Landscape & Forecast – Disease Landscape & Forecast
Gout is a painful, systemic inflammatory condition caused by elevated serum uric acid and characterized by intermittent acute flares. Treatment of acute gout flares typically involves NSAIDs, colchicine, corticosteroids, and anti-IL-1 agents. Long-term urate-lowering drugs (ULDs), such as xanthine oxidase inhibitors (XOIs), uricosuric agents, and uricase analogues, are the cornerstone of chronic gout management. Despite the availability of these treatments, substantial opportunity remains for agents that are less frequently dosed, agents with safer profiles, and agents to treat chronic refractory gout. This therapy market will expand over the 2022-2032 study period, fueled by an increasing diagnosed gout population and demand for new drugs that can effectively, safely, and conveniently control the disease. Several drugs are in clinical development, including uricase analogues, XOIs, URAT1 inhibitors, and inhibitors of the NOD-like receptor protein-3 (NLRP3) inflammasome.
QUESTIONS ANSWERED
- What are the incidence and prevalence of gout in the major pharmaceutical markets under study?
- How is gout currently treated? What are experts’ opinions of Horizon Pharma’s Krystexxa as a treatment for chronic refractory gout?
- What is the commercial potential of emerging therapies? How do leaders in the field of gout management rate these drug candidates?
- How will the gout therapy market evolve over the next 10 years?
CONTENT HIGHLIGHTS
- Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
- Primary research: 19 country-specific interviews with thought-leading rheumatologists. Supported by survey data collected for this and other Clarivate research.
- Epidemiology: Incidence and prevalence of diagnosed gout population by country and drug-treated rates.
- Emerging therapies: Coverage of select emerging therapies from preclinical to preregistration stages.
- Market forecast features: 10-year, annualized, drug-level sales and patient share of key gout therapies through 2032, segmented by brands / generics.
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
SOLUTION ENHANCEMENT
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold. Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Gout - Landscape & Forecast - Disease Landscape & Forecast
- Key Findings
- Key Updates
- Market Outlook
- Key findings
- Market drivers and constraints
- What factors are driving the market for gout?
- What factors are constraining the market for gout?
- Key market events for gout: 2022-2032
- Total gout sales by populations in the major markets: 2022-2032
- Total sales by drug class for chronic gout in the major markets: 2022-2032
- Patient share by drug class for chronic gout in the major markets: 2022-2032
- Drug-class-specific trends
- Forecast
- Etiology and Pathophysiology
- Epidemiology
- Current Treatment
- Unmet Need Overview
- Drug pipeline
- Access & Reimbursement Overview
- Emerging Therapies
- Methodology
- Appendix
Tej Pal, M.Pharm., is a senior healthcare research & data analyst on the Cardiovascular, Metabolic, Renal, and Hematologic Diseases team at Clarivate. He has authored several reports focusing on metabolic and renal indications. Previously, he was an analyst at IQVIA and at Smart Analyst Inc., where he worked closely with top pharmaceutical companies on commercial and technical ad-hoc requests. During his tenure there, he delivered competitive landscape and market insight projects on various oncology indications. He holds a master’s degree in pharmacy with a specialization in pharmaceutical chemistry from the Delhi Institute of Pharmaceutical Sciences and Research in New Delhi, India.